MERI KRYSS: Open Payments
NPI 1750499471 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$340 in 18 payments from 7 companies in 2025. Trend: 2023 $322 · 2024 $312 · 2025 $340
Food & beverage: $340
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $112 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $19 |
Products named: LINZESS, ZENPEP, GEMTESA, REXULTI, CREON, ZORYVE, VOQUEZNA, IBSRELA.
Industry payments across PA — which companies pay providers there.
